Summit Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $12.12B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 19, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 23, 2026 | After market close | – | $-0.28 | $-0.19 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | After market close | – | $-0.24 | $-0.15 |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 20, 2025 | Before market open | – | $-0.31 | $-0.13 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | – | $-0.76 | $-0.12 |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | After market close | – | $-0.09 | $-0.07 |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | Before market open | – | $-0.08 | $-0.05 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | $-0.09 | $-0.05 |
| Q1 FY2024 Ended Mar 31, 2024 | May 1, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 20, 2024 | Before market open | – | – | – |
Press releases
Announcements Summit Therapeutics filed with the SEC
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Summit Therapeutics Q2 2026 Earnings Call July 23, 2026 4:30pm ET
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Summit Therapeutics ASCO 2026 Update Call June 1, 2026 7:00am ET
Other events · EX-99.3 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Summit Therapeutics Q4 & FY 2025 Earnings Call February 23, 2026 4:30pm ET
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
44th Annual J.P. Morgan Healthcare Conference January 12, 2026 BOB DUGGAN Chairman & Co-Chief Executive Officer DR. MAKY ZANGANEH President & Co-Chief Executive Officer
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Summit Therapeutics Raises $500 Million in Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Other events · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Other events · EX-99.3 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Summit Therapeutics WCLC Update Call September 8, 2025 8:00am ET
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Summit Therapeutics Q1 2025 Earnings Call May 1, 2025 4:30pm ET
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
VEGF – Vascular Endothelial Growth Factor is a signaling protein that promotes angiogenesis.8 8 Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2011 Dec;2(12):1097-105.
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Summit Therapeutics Q4 & YE 2024 Earnings Call February 24, 2025 9:00am ET
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 Mission Vision BOB DUGGAN, Chairman & CEO DR. MAKY ZANGANEH, CEO & President
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Summit Therapeutics Q3 2024 Earnings Call October 30, 2024 9:00am ET
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Summit Therapeutics Raises $235 Million
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Changli Wang | A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable Non-Small Cell Lung Cancer 5 Baseline Characteristics
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K